Flex Pharma (FLKS) Offers Regulatory, Clinical Update for FLX-787 for Treatment of Nocturnal Leg Cramp

Go back to Flex Pharma (FLKS) Offers Regulatory, Clinical Update for FLX-787 for Treatment of Nocturnal Leg Cramp

Cantor Fitzgerald Downgrades Flex Pharma (FLKS) to Hold

October 14, 2016 8:44 AM EDT

Cantor Fitzgerald downgraded Flex Pharma (NASDAQ: FLKS) from Buy to Hold with a price target of $10.00 (from $22.00).

For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.

Shares of Flex Pharma closed at $8.43 yesterday.

... More